plerixafor has been researched along with ginsenoside rb1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Huang, MT; Lan, TH; Li, M; Song, JX; Wu, HL; Xu, DP | 1 |
2 other study(ies) available for plerixafor and ginsenoside rb1
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Ginsenoside Rb1 prevents homocysteine-induced EPC dysfunction via VEGF/p38MAPK and SDF-1/CXCR4 activation.
Topics: Animals; Benzylamines; Cell Movement; Cell Survival; Chemokine CXCL12; Cyclams; Endothelial Progenitor Cells; Ginsenosides; Heterocyclic Compounds; Homocysteine; Indoles; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |